-
Mashup Score: 1ASCO Congratulates 2024 Special Awards Recipients - 8 hour(s) ago
ASCO and Conquer Cancer will honor individuals who have significantly impacted global cancer care across various domains at the 2024 ASCO Annual Meeting.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers - 1 day(s) ago
Background: Germline genetic testing is a vital component of guideline-recommended cancer care for males with pancreatic, breast, or metastatic prostate cancers. We sought to determine whether there were racial disparities in germline genetic testing completion in this population. Patients and Methods: This retrospective cohort study included non-Hispanic White and Black males with incident pancreatic, breast, or metastatic prostate cancers between January 1, 2019, and September 30, 2021. Two nationwide cohorts were examined: (1) commercially insured individuals in an administrative claims database, and (2) Veterans receiving care in the Veterans Health Administration. One-year germline genetic testing rates were estimated by using Kaplan-Meier methods. Cox proportional hazards regression was used to test the association between race and genetic testing completion. Causal mediation analyses were performed to investigate whether socioeconomic variables contributed to associations betwee
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet-
New @JNCCN by Jeff Shevach @DukeGUCancer, @KMaxwellLab & me @Penn: Disparities in precision #oncology arise from disparities in access. We find Black-White disparities in germline testing for men with commercial insurance, NOT equal-access @DeptVetAffairs https://t.co/xyr1NQzoM7 https://t.co/JUinMFC9ZK
-
-
Mashup Score: 1ASCO Congratulates 2024 Special Awards Recipients - 2 day(s) ago
ASCO and Conquer Cancer will honor individuals who have significantly impacted global cancer care across various domains at the 2024 ASCO Annual Meeting.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Parsaclisib Added to Ruxolitinib Decreases Spleen Volume and Improves Symptom Scores in Myelofibrosis - 2 day(s) ago
Add-on parsaclisib with ruxolitinib resulted in decreased spleen volume and improved symptom assessment scores in patients with myelofibrosis.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Utilizing obinutuzumab to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic graft-vs-host disease undergoing well-matched hematopoietic stem cell transplant.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert Dermatopathologist - 2 day(s) ago
Phyu Aung, MD, PhD, FCAP, a dermatopathologist, discusses key challenges in diagnosing and treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Definitive diagnosis is difficult given BPDCN’s heterogeneous features and frequent skin and CNS involvement. Recent advances have utilized immunophenotyping and targeted CD123, which is overexpressed on BPDCN cells. However, resistance develops with CD123 monotherapy. She notes that while testing aids BPDCN insights, more prognostic markers are needed, and emphasizes that continued cross-disciplinary research is critical to better outcomes.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1California Doctor Receives Northwestern Medicine’s First Combined Lung-Liver Transplant for Advanced Lung Cancer - 3 day(s) ago
Gary Gibbon, MD, pulmonologist and allergist, visited Chicago for a first-of-its-kind transplant procedure, becoming the first person in the U.S. to receive a double-lung and liver transplant for advanced lung cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15
Durvalumab plus chemotherapy produced superior 3-year survival outcomes vs chemotherapy alone in advanced biliary tract cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Dr Petrylak on the Shifting Role of Avelumab Maintenance in Metastatic Urothelial Cancer - 4 day(s) ago
Daniel Petrylak, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the use of avelumab maintenance in urothelial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
.@ASCO Congratulates 2024 Special Awards Recipients @cityofhope #oncology https://t.co/JG9e1rXHm5